Literature DB >> 11158613

A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys.

P V Vaitkevicius1, M Lane, H Spurgeon, D K Ingram, G S Roth, J J Egan, S Vasan, D R Wagle, P Ulrich, M Brines, J P Wuerth, A Cerami, E G Lakatta.   

Abstract

Nonenzymatic glycosylation and cross-linking of proteins by glucose contributes to an age-associated increase in vascular and myocardial stiffness. Some recently sythesized thiazolium compounds selectively break these protein cross-links, reducing collagen stiffness. We investigated the effects of 3-phenacyl-4,5-dimethylthiazolium chloride (ALT-711) on arterial and left ventricular (LV) properties and their coupling in old, healthy, nondiabetic Macaca mulatta primates (age 21 +/- 3.6 years). Serial measurements of arterial stiffness indices [i.e., aortic pulse wave velocity (PWV) and augmentation (AGI) of carotid arterial pressure waveform] as well as echocardiographic determinations of LV structure and function were made before and for 39 weeks after 11 intramuscular injections of ALT-711 at 1.0 mg/kg body weight every other day. Heart rate, brachial blood pressure, and body weight were unchanged by the drug. PWV and AGI decreased to a nadir at 6 weeks [PWV to 74.2 +/- 4.4% of baseline (B), P = 0.007; AGI to 41 +/- 7.3% of B, P = 0.046], and thereafter gradually returned to baseline. Concomitant increases in LV end diastolic diameter to 116.7 +/- 2.7% of B, P = 0.02; stroke volume index (SV(index)) to 173.1 +/- 40.1% of B, P = 0.01; and systolic fractional shortening to 180 +/- 29.7% of B, P = 0.01 occurred after drug treatment. The LV end systolic pressure/SV(index), an estimate of total LV vascular load, decreased to 60 +/- 12.1% of B (P = 0.02). The LV end systolic diameter/SV(index), an estimate of arterio-ventricular coupling, was improved (decreased to 54.3 +/- 11% of B, P < 0.002). Thus, in healthy older primates without diabetes, ALT-711 improved both arterial and ventricular function and optimized ventriculo-vascular coupling. This previously unidentified cross-link breaker may be an effective pharmacological therapy to improve impaired cardiovascular function that occurs in the context of heart failure associated with aging, diabetes, or hypertension, conditions in which arterial and ventricular stiffness are increased.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158613      PMCID: PMC14727          DOI: 10.1073/pnas.98.3.1171

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Pulse pressure: Is this a clinically useful risk factor?

Authors:  M O'Rourke; E D Frohlich
Journal:  Hypertension       Date:  1999-09       Impact factor: 10.190

2.  An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

Authors:  M Asif; J Egan; S Vasan; G N Jyothirmayi; M R Masurekar; S Lopez; C Williams; R L Torres; D Wagle; P Ulrich; A Cerami; M Brines; T J Regan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 3.  Advanced glycosylation: chemistry, biology, and implications for diabetes and aging.

Authors:  R Bucala; A Cerami
Journal:  Adv Pharmacol       Date:  1992

4.  Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery.

Authors:  R P Kelly; H H Gibbs; M F O'Rourke; J E Daley; K Mang; J J Morgan; A P Avolio
Journal:  Eur Heart J       Date:  1990-02       Impact factor: 29.983

Review 5.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

Review 6.  Cardiovascular regulatory mechanisms in advanced age.

Authors:  E G Lakatta
Journal:  Physiol Rev       Date:  1993-04       Impact factor: 37.312

7.  Effective arterial elastance as index of arterial vascular load in humans.

Authors:  R P Kelly; C T Ting; T M Yang; C P Liu; W L Maughan; M S Chang; D A Kass
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

8.  Optimal arterial resistance for the maximal stroke work studied in isolated canine left ventricle.

Authors:  K Sunagawa; W L Maughan; K Sagawa
Journal:  Circ Res       Date:  1985-04       Impact factor: 17.367

9.  Effects of age and aerobic capacity on arterial stiffness in healthy adults.

Authors:  P V Vaitkevicius; J L Fleg; J H Engel; F C O'Connor; J G Wright; L E Lakatta; F C Yin; E G Lakatta
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

10.  Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.

Authors:  Y M Li; M Steffes; T Donnelly; C Liu; H Fuh; J Basgen; R Bucala; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

View more
  57 in total

1.  Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction.

Authors:  Doron Aronson
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

Review 2.  Trends in advanced glycation end products research in diabetes mellitus and its complications.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-03-23       Impact factor: 3.396

Review 3.  Views from within and beyond: narratives of cardiac contractile dysfunction under senescence.

Authors:  Xiaoping Yang; Nair Sreejayan; Jun Ren
Journal:  Endocrine       Date:  2005-03       Impact factor: 3.633

Review 4.  Ventriculovascular coupling in systolic and diastolic heart failure.

Authors:  Justin M Fox; Mathew S Maurer
Journal:  Curr Heart Fail Rep       Date:  2005-12

5.  Novel therapeutic strategies for reducing arterial stiffness.

Authors:  Carmel M McEniery
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

6.  Ventriculovascular coupling in systolic and diastolic heart failure.

Authors:  Justin M Fox; Mathew S Maurer
Journal:  Curr Cardiol Rep       Date:  2006-05       Impact factor: 2.931

7.  The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial.

Authors:  Madelijn H Oudegeest-Sander; Marcel G M Olde Rikkert; Paul Smits; Dick H J Thijssen; Arie P J van Dijk; Benjamin D Levine; Maria T E Hopman
Journal:  Exp Gerontol       Date:  2013-12       Impact factor: 4.032

8.  Hyperglycemia and arterial stiffness: the Atherosclerosis Risk in the Communities study.

Authors:  Jonathan Rubin; Vijay Nambi; Lloyd E Chambless; Michael W Steffes; Stephen P Juraschek; Josef Coresh; A Richey Sharrett; Elizabeth Selvin
Journal:  Atherosclerosis       Date:  2012-09-13       Impact factor: 5.162

9.  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.

Authors:  J L Figarola; S Scott; S Loera; C Tessler; P Chu; L Weiss; J Hardy; S Rahbar
Journal:  Diabetologia       Date:  2003-07-05       Impact factor: 10.122

10.  Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats.

Authors:  Kuo-Chu Chang; Kwan-Lih Hsu; Tsai-Fwu Chou; Huey-Ming Lo; Yung-Zu Tseng
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.